Neotherapuetics possibly has a breakthrough drug - NEOT Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Neotherapuetics possibly has a breakthrough drug - NEOT

NEOT 1.919

+4.3%

Jan 17 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: tuck who wrote (169)	4/10/2001 11:39:37 AM
From: Marty	Read Replies (1) of 204

Raging Bull post: Boy! It's hard to believe. NEOT is finally in pivotal trials for FDA approval. It has been a long hard ride but the constellations are moving into alignment. Going in, this pivotal trial already has ample preliminary evidence from a good number of previous trials that the drug is safe and effective. The end is in sight. The PR is much stronger now and the story is spreading. Hopefully, the financing problems are behind them. It looks like they are going to make the right decision on the warrants and secure additional financing from the best source at good terms, still twice as high as current value. They have trials for Parkinsons and spinal cord injury using Neotrofin already underway. They already know the drug is safe and have good evidence it should be effective. The learning curve is kicking in. They have world recognized leaders in field on staff for both clinical work and others experienced in bringing drugs through the FDA approval process all the way to market. They have two other very promising separate subsidiaries working on oncology and genomics ... one of the most promising prospects in the history of medicine. They have over 10 peer reviewed articles already in the publishing pipeline that will get them whatever recognition and credibility that is withheld without them. They have a major investor from Speer, Leeds and Kellogg heavily involved. Since that firm was purchased a year or so ago by Goldman Sachs you could logically expect marketmaking, analysis, and investment banking to be available for NEOT. They still have at least a 3 year lead on everybody else in the field. It should be a good year, followed by a fantastic one.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next